Smallpox vaccination: Risk considerations for patients with atopic dermatitis

Journal of Allergy and Clinical Immunology

Volumn 110, Issue 3, 2002, Pages 357-365

  Engler, Renata J M ^a   Kenner, Julie ^b   Leung, Donald Y M ^c,d  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b TRIPLER ARMY MEDICAL CENTER   (United States)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

Atopic dermatitis; Eczema; Smallpox; T cells; Vaccinia

Indexed keywords

SMALLPOX VACCINE;

ATOPIC DERMATITIS; BIOLOGICAL WARFARE; ECZEMA; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SMALLPOX; T LYMPHOCYTE; VACCINATION;

EID: 0036736815     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2002.128052     Document Type: Article

References (73)

1. Fritz SB, Singer AM, Revan VB, Baker JR Jr. Bioterrorism: relevance to allergy and immunology in clinical practice. J Allergy Clin Immunol 2002;109:214-28.
2. Drazen JM. Smallpox and bioterrorism. N Engl J Med 2002;346:1262-3.
3. Breman JG, Henderson DA. Diagnosis and management of smallpox. N Engl J Med 2002;346:1300-8.
4. Bicknell WJ. The case for voluntary smallpox vaccination. N Engl J Med 2002;346:1323-5.
5. Cohen J. Bioterrorism. Smallpox vaccinations: how much protection remains? Science 2001;294:985.
6. Albert MR, Ostheimer KG, Breman JG. The last smallpox epidemic in Boston and the vaccination controversy, 1901-1903. N Engl J Med 2001;344:375-9.
7. Fauci AS. Smallpox vaccination policy - the need for dialogue. N Engl J Med 2002;346:1319-20.
8. Henderson DA, Moss B. Smallpox and vaccinia. In: Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. Philadelphia: WB Saunders; 1999. p. 74-97.
9. Kempe CH. Studies on smallpox and complications of smallpox vaccination. Pediatrics 1960;26:176-89.
10. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox and its eradication. In: The pathogenesis, immunology and pathology of smallpox and vaccinia. Geneva: World Health Organization; 1988. p. 122-67.
11. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J Infect Dis 1970;122:303-9.
12. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. N Engl J Med 1969;281:1201-8.
13. Lane JM, Millar JD, Neff JM. Smallpox and smallpox vaccination policy. Annu Rev Med 1971;22:251-72.
14. Vaccinia (smallpox vaccine) recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. (RR-10). MMWR 2001;50:1-22.
15. Haim M, Gdalevich M, Mimouni D, Ashkenazi I, Shemer J. Adverse reactions to smallpox vaccine: the Israel Defense Force Experience, 1991-1996. A comparison with previous surveys. Mil Med 2000;165:287-9.
16. Nakano JH. Human poxvirus diseases. In: Lennette EH, editor Laboratory diagnosis of viral infection. New York: Marcel Dekker; 1985. p. 401-23.
17. Alcami A, Koszinowski UH. Viral mechanisms of immune evasion. Trends Microbiol 2000;8:410-8.
18. Bowie A, Kiss-Toth E, Symons JA, Smith GL, Dower SK. O'Neill LA. A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc Natl Acad Sci U S A 2000;97:10163-7.
19. McKee PH. Pathology of the skin with clinical correlations. 2nd ed. London: Mosby-Wolfe: 1996. p. 4-14.
20. Barnhill RL. Textbook of dermatopathology. New York: McGraw-Hill: 1998.
21. Bras G. Observations on the formation of smallpox scars. Arch Pathol 1952;54:149-56.
22. Copeman PWM, Wallace HJ. Eczema vaccinatum. Br Med J 1964;2:906-8.
23. Lane JM, Millar JD. Risks of smallpox vaccination complications in the United States. Am J Epidemiol 1971;93:238-40.
24. Hill LW. Evolution of atopic dermatitis. Arch Dermatol 1935;32:451-5.
25. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Dermatol Venereol (Stockh) 1980;92:44-7.
26. Schultz Larsen F, Hanifin JM. Epidemiology of atopic dermatitis. Immunol Allergy Clin North Am 2002;22:1-24.
27. Walker RB, Warin RP. Incidence of eczema in early childhood. Br J Dermatol 1956;68:183-4.
28. Taylor B, Wadsworth J, Wadsworth M, Peckham C. Changes in the reported prevalence of childhood eczema since the 1939-45 war. Lancet 1984;2:1255-7.
29. Laughter D, Istvan JA, Tofte SJ, Hanifin JM. The prevalence of atopic dermatitis in Oregon schoolchildren. J Am Acad Dermatol 2000;43:649-55.
30. Sugiura H, Umemoto N, Deguchi H, Murata Y, Tanaka K, Sawai T, et al. Prevalence of childhood and adolescent atopic dermatitis in a Japanese population: comparison with the disease frequency examined 20 years ago. Acta Derm Venereol 1998;78:293-4.
31. Kempe CH. Studies on smallpox and complications of smallpox vaccination. Pediatrics 1968;26:176-89.
32. McCarthy D, Downie AW, Bradley WH. The antibody response in man following infection with viruses of the pox group. II. Antibody response following vaccination. J Hyg 1958;56:466-78.
33. Downie AW, Saint Vincent L, Goldstein L, Rao AR, Kempe CH. Antibody response in non-haemorrhagic smallpox patients. J Hyg (Lond) 1969;67:609-18.
34. Downie AW, McCarthy K. The antibody response in man following infection with viruses of the pox group. III. Antibody response in smallpox. J Hyg 1958;56:479-87.
35. Downie AW, Fedson DS. Saint Vincent L, Rao AR, Kempe CH. Haemorrhagic smallpox. J Hyg (Lond) 1969;67:619-29.
36. Jackson TM, Zaman SN, Huq F. T and B rosetting lymphocytes in the blood of smallpox patients. Am J Trop Med Hyg 1977;26:517-9.
37. Blanden RV. T cell response to viral and bacterial infection. Transplant Rev 1974;19:56-88.
38. Cole GA, Blanden RV. Immunology of poxviruses. In: Hahmias AJ, O'Reilly RJ, editors. Comprehensive immunology. New York: Plenum Press: 1982. p. 1-19.
39. Binder D, Kundig TM. Antiviral protection by CD8+ versus CD4+ T cells. CD8+ T cells correlating with cytotoxic activity in vitro are more efficient in antivaccinia virus protection than CD4-dependent IL. J Immunol 1991;146:4301-7.
40. Ennis FA, Cruz J, Demkowicz WE Jr, Rothman AL, McClain DJ. Primary induction of human CD8+ cytotoxic T lymphocytes and interferon-gamma-producing T cells after smallpox vaccination. J Infect Dis 2002;185:1657-9.
41. Karupiah G, Xie QW, Buller RM, Nathan C, Duarte C, MacMicking JD. Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science 1993;261:1445-8.
42. Mahalingam S, Foster PS, Lobigs M, Farber JM, Karupiah G. Interferon-inducible chemokines and immunity to poxvirus infections. Immunol Rev 2000;177:127-33.
43. Ruby J, Ramshaw I. The antiviral activity of immune CD8+ T cells is dependent on interferon-gamma. Lymphokine Cytokine Res 1991;10:353-8.
44. Tanaka-Kataoka M, Kunikata T, Takayama S, Iwaki K, Ohashi K, Ikeda M, et al. In vivo antiviral effect of interleukin 18 in a mouse model of vaccinia virus infection. Cytokine 1999;11:593-9.
45. Bastian A, Schafer H. Human alpha-defensin 1 (HNP-1) inhibits adenoviral infection in vitro. Regul Pept 2001;101:157-61.
46. Biron CA. Brossay L. NK cells and NKT cells in innate defense against viral infections. Curr Opin Immunol 2001;13:458-64.
47. Selin LK, Santolucito PA, Pinto AK, Szomolanyi-Tsuda E, Welsh RM, Innate immunity to viruses: control of vaccinia virus infection by gamma delta T cells. J Immunol 2001;166:6784-94.
48. McClain DJ, Harrison S, Yeager CL, Cruz J, Ennis FA, Gibbs P, et al. Immunologic responses to vaccinia vaccines administered by different parenteral routes. J Infect Dis 1997;175:756-63.
49. Galasso GJ, Mattheis MJ, Cherry JD, Connor JD, McIntosh K, Benenson AS, et al. Clinical and serologic study of four smallpox vaccines comparing variations of dose and route of administration. Summary. J Infect Dis 1977;135:183-6.
50. el-Ad B, Roth Y, Winder A, Tochner Z, Lublin-Tennenbaum T, Katz E, et al. The persistence of neutralizing antibodies after revaccination against smallpox. J Infect Dis 1990;161:446-8.
51. Demkowicz WE Jr, Ennis FA. Vaccinia virus-specific CD8+ cytotoxic T lymphocytes in humans. J Virol 1993;67:1538-44.
52. Demkowicz WE Jr, Littaua RA, Wang J, Ennis FA. Human cytotoxic T-cell memory: long-lived responses to vaccinia virus. J Virol 1996;70:2627-31.
53. Mack TM, Noble J Jr, Thomas DB. A prospective study of serum antibody and protection against smallpox. Am J Trop Med Hyg 1972;21:214-8.
54. Raychaudhuri SP, Raychaudhuri SK. Revisit to Kaposi's varicelliform eruption: role of IL-4. Int J Dermatol 1995;34:854-6.
55. Jackson RJ, Ramsay AJ, Christensen CD, Beaton S, Hall DF, Ramshaw IA. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J Virol 2001;75:1205- 10.
56. Sharma DP, Ramsay AJ, Maguire DJ, Rolph MS, Ramshaw IA. Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo. J Virol 1996;70:7103-7.
57. Leung DY. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000;105:860-76.
58. Hamid Q, Naseer T, Minshall EM, Song YL, Boguniewicz M, Leung DY. In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy Clin Immunol 1996;98:225-31.
59. Hamid Q, Boguniewicz M, Leung DYM. Differential cytokine gene expression in acute vs chronic atopic dermatitis. J Clin Invest 1994;94:870-6.
60. Higashi N, Gesser B, Kawana S. Thestrup-Pedersen K. Expression of IL-18 mRNA and secretion of IL-18 are reduced in monocytes from patients with atopic dermatitis. J Allergy Clin Immunol 2001;108:607-14.
61. Leung DY, Wood N, Dubey D, Rhodes AR, Geha RS. Cellular basis of defective cell-mediated lympholysis in atopic dermatitis. J Immunol 1983;130:1678-82.
62. Kimura M, Tsuruta S, Yoshida T. Unique profile of IL-4 and 1FN-gamma production by peripheral blood mononuclear cells in infants with atopic dermatitis. J Allergy Clin Immunol 1998;102:238-44.
63. Campbell DE, Fryga AS, Bol S, Kemp AS. Intracellular interferon-gamma (lFN-gamma) production in normal children and children with atopic dermatitis. Clin Exp Immunol 1999;115:377-82.
64. Lever RS, Lesko MJ, MacKie RM, Parrott DM. Natural killer cell activity in atopic dermatitis: a sequential study. Clin Allergy 1985;15:479-86.
65. Ambach A, Bonnekoh B, Gollnick H. Perforin hyperreleasability and depletion in cytotoxic T cells from patients with exacerbated atopic dermatitis and asymptomatic rhinoconjunctivitis allergica. J Allergy Clin Immunol 2001;107:878-86.
66. Kagi D, Seiler P, Pavlovic J, Ledermann B, Burki K, Zinkemagel RM, et al. The roles of perforin- and Fas-dependent cytotoxicity in protection against cytopathic and noncytopathic viruses. Eur J Immunol 1995;25:3256-62.
67. Giustizieri ML, Mascia F, Frezzolini A, De Pita O, Chinni LM, Guannetti A, et al. Kertinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J Allergy Clin Immunol 2001;107:871-7.
68. Ong PY, Strickland I, Boguniewicz M, Kisich KO, Leung DYM. Reduced expression of human β defensin-2 (HBD-2) and CCR6 in atopic dermatitis (AD). J Allergy Clin Immunol 2002;109(1 pt 2);779A.
69. von Bubnoff D, Geiger E, Bieber T. Antigen-presenting cells in allergy. J Allergy Clin Immunol 2001;108:329-39.
70. Geiger E, Magerstaedt R, Wessendoff JH, Kraft S, Hanau D, Bieber T. IL-4 induces the intracellular expression of the alpha chain of the high-affinity receptor for IgE in in vitro-generated dendritic cells. J Allergy Clin Immunol 2000;105:150-6.
71. Arkwright PD. Chase JM, Babbage S, Pravica V, David TJ, Hutchinson IV. Atopic dermatitis is associated with a low-producer transforming growth factor β1 cytokine genotype. J Allergy Clin Immunol 2001;108:281-4.
72. Ohmen JD, Hanifin JM, Nickoloff BJ, Rea TH, Wyzykowski R. Kim J, et al. Overexpression of IL-10 in atopic dermatitis. Contrasting cytokine patterns with delayed-type hypersensitivity reactions. J Immunol 1995;154:1956-63.
73. Stittelaar KJ. Osterhaus AD. MVA: a cuckoo in the vaccine nest? Vaccine 2001;19:5-6.